The introduction of specific BCR-ABL inhibitors in chronic myelogenous leukemia therapy has entirely mutated the prognosis of this hematologic cancer from being a fatal disorder to becoming a chronic disease. The gene discussed is ABL1; the disease is hematopoietic and lymphoid cell neoplasm.